Tafazzin is a phospholipid-lysophospholipid transacylase that plays a pivotal role in the remodeling of cardiolipin, a unique phospholipid essential for the optimal function of mitochondrial membranes. Cardiolipin is crucial for maintaining the structural integrity and fluidity of the mitochondrial inner membrane, facilitating efficient electron transport in oxidative phosphorylation, and stabilizing mitochondrial membrane proteins, including those involved in the assembly of respiratory chain complexes. Tafazzin's activity ensures the proper maturation of cardiolipin by adjusting its acyl chain composition, a process vital for the energetic efficiency of mitochondria and the maintenance of cellular metabolic homeostasis. Dysfunction or deficiency in tafazzin is associated with altered mitochondrial morphology and function, highlighting its importance in bioenergetic processes and the potential consequences of its impaired activity on cellular health.
The inhibition of tafazzin involves mechanisms that disrupt its enzymatic activity or interfere with its substrate interaction, leading to aberrant cardiolipin remodeling and mitochondrial dysfunction. Inhibitors may act by directly binding to the active site of tafazzin, thereby preventing the enzyme from catalyzing the transfer of acyl groups to cardiolipin. Alternatively, inhibition can occur through the modulation of pathways that indirectly affect tafazzin's function or expression, such as altering the availability of its lipid substrates or influencing post-translational modifications that regulate enzyme activity. The consequences of tafazzin inhibition extend beyond the immediate disruption of cardiolipin synthesis, impacting mitochondrial dynamics, respiration, and apoptosis regulation. Understanding the mechanisms of tafazzin inhibition provides insights into the complex interplay between lipid metabolism and mitochondrial function and underscores the significance of precise regulatory controls in maintaining cellular and organismal homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Tamoxifen inhibits tafazzin by interfering with cardiolipin metabolism, a key process in maintaining mitochondrial structure and function, suggesting a direct mechanism of action on mitochondrial phospholipid remodeling. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate (EGCG) inhibits tafazzin by its antioxidant properties, potentially reducing oxidative stress-related damage to cardiolipin and thus affecting mitochondrial function and cardiolipin-dependent processes. | ||||||
Bezafibrate | 41859-67-0 | sc-204650B sc-204650 sc-204650A sc-204650C | 500 mg 1 g 5 g 10 g | $31.00 $46.00 $122.00 $204.00 | 5 | |
Bezafibrate inhibits tafazzin activity by impacting mitochondrial function and cardiolipin metabolism, suggesting a mechanism that involves the alteration of lipid homeostasis within the mitochondria. | ||||||